scholarly journals Perturbed MafB/GATA1 axis after burn trauma bares the potential mechanism for immune suppression and anemia of critical illness

2016 ◽  
Vol 100 (4) ◽  
pp. 725-736 ◽  
Author(s):  
Nicholas B. Johnson ◽  
Joseph A. Posluszny ◽  
Li K. He ◽  
Andrea Szilagyi ◽  
Richard L. Gamelli ◽  
...  
Author(s):  
Mark W Hall ◽  
Ila Joshi ◽  
Luis Leal ◽  
Eng Eong Ooi

Abstract We are learning that the host response to severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2) infection is complex and highly dynamic. Effective initial host defense in the lung is associated with mild symptoms and disease resolution. Viral evasion of the immune response can lead to refractory alveolar damage, ineffective lung repair mechanisms, and systemic inflammation with associated organ dysfunction. The immune response in these patients is highly variable and can include moderate to severe systemic inflammation and/or marked systemic immune suppression. There is unlikely to be a “one size fits all” approach to immunomodulation in patients with coronavirus disease 2019 (COVID-19). We believe that a personalized, immunophenotype-driven approach to immunomodulation that may include anticytokine therapy in carefully selected patients and immunostimulatory therapies in others is the shortest path to success in the study and treatment of patients with critical illness due to COVID-19.


Shock ◽  
2018 ◽  
Vol 49 (3) ◽  
pp. 249-258 ◽  
Author(s):  
Julie A. Stortz ◽  
Tyler J. Murphy ◽  
Steven L. Raymond ◽  
Juan C. Mira ◽  
Ricardo Ungaro ◽  
...  

2012 ◽  
Vol 13 (2) ◽  
pp. 165-173 ◽  
Author(s):  
Joseph A. Carcillo ◽  
J. Michael Dean ◽  
Richard Holubkov ◽  
John Berger ◽  
Kathleen L. Meert ◽  
...  

2016 ◽  
Vol 25 (1) ◽  
pp. 85-92 ◽  
Author(s):  
Kristin C. Greathouse ◽  
Mark W. Hall

Critical illness comprises a heterogeneous group of serious medical conditions that typically involve an initial proinflammatory process. A compensatory anti-inflammatory response may occur that, if severe and persistent, places the patient at high risk for adverse outcomes including secondary infection and death. Monitoring strategies can identify these patients through measurement of innate and adaptive immune function. Reductions in monocyte HLA-DR expression, reduced cytokine production capacity, increased inhibitory cell surface molecule expression, and lymphopenia have all been associated with this immune-suppressed state. Intriguing data suggest that critical illness–induced immune suppression may be reversible with agents such as interferon-γ, granulocyte macrophage colony-stimulating factor, interleukin 7, or anti–programmed death-1 therapy. Future approaches for characterization of patient-specific immune derangements and individualized treatment could revolutionize how we recognize and prevent complications in critically ill patients.


Sign in / Sign up

Export Citation Format

Share Document